SCHEDULE: Vestal Point Capital Trims Stake in Immatics N.V.

Vestal Point Capital, LP has reduced its ownership in Immatics N.V. to 4.6%, crossing below the 5% regulatory reporting threshold.

Summary

• Vestal Point Capital, LP and Managing Partner Ryan Wilder disclosed a reduced ownership position in Immatics N.V. (IMTX).
• The reporting persons now hold 6,175,000 ordinary shares, down from a previously higher level.
• This position represents 4.6% of the 134,071,432 total ordinary shares outstanding as of the end of 2025.
• The shares are held for passive investment purposes in the ordinary course of business and not to influence corporate control.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as slightly cautious, as a major institutional investor has reduced their stake to below the 5% threshold, though they remain a significant shareholder.

Positives

• Vestal Point Capital remains a significant institutional shareholder with over 6 million shares.
• The investment is maintained in the ordinary course of business, indicating a stable, non-activist stance.

Negatives

• Ownership has dropped below the 5% threshold, which may signal a reduction in institutional conviction.
• The reduction in stake could precede further selling by the investment manager as they rebalance their portfolio.

Risks

• Institutional selling can create technical downward pressure on the stock price.
• Falling below the 5% threshold reduces the transparency requirements for future trades by this specific investor.

Future Outlook

No specific forward-looking guidance is provided in this ownership disclosure; the reporting persons certify the shares were not acquired to influence control of the issuer.

Management Comments

• The securities were acquired and are held in the ordinary course of business.
• The securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that institutional rebalancing is common in the biotechnology sector, where funds often adjust positions following clinical data readouts or to manage portfolio risk.

Comparison to Industry Standards

• A 4.6% stake remains a significant institutional position compared to average retail holdings.
• Many institutional investors in the biotech space, such as those in peers like Adaptimmune Therapeutics, maintain positions between 3% and 7%.
• The move below 5% aligns with standard portfolio management practices for hedge funds and investment advisers.

Stakeholder Impact

• Shareholders may see this as a sign of institutional profit-taking or portfolio rebalancing.
• The company loses a '5% or greater' institutional backer, which can impact market perception.

Next Steps

• Monitor future 13F filings for further changes in Vestal Point Capital's position.
• Watch for similar moves by other institutional holders of Immatics N.V.

Key Dates

Recommendation

A reduction in stake to 4.6% by a passive investor is a routine portfolio adjustment and does not inherently signal a change in the company's fundamental value or clinical prospects.

Keywords

Immatics N.V., Vestal Point Capital, Ryan Wilder, Institutional Ownership, Biotechnology, Schedule 13G, Equity Stake